Because of a lack of therapeutically efficacious MYC inhibitors (Li & Simon, 2013), we propose the inhibition of MYC downstream targets, in particular GLS1, as an effective strategy to overcome acquired tolerance and resistance of cancer cells to CDK4/6 inhibitors. Here, GLS is linked to cancer.